קפיטליזציית שוק: AC Immune (ACIU)

The share price of AC Immune (ACIU) visualized below belongs to the biopharma sector, where the company combats neuronal degeneration. The current figure stands at 0.23, however, the firm's survival depends on the outcome of Alzheimer's drug trials and the rate of cash burn. The absence of commercial revenue deprives it of pricing power, but patents create potential for future deals with industry behemoths. The primary risk is a possible research collapse amid a liquidity shortage.

Market capitalization represents the aggregate value of all a business's shares, defining its absolute scale within the capital structure. Analyzing the market capitalization of a company allows for the identification of abnormal price deviations from fundamental values. Sharp spikes on the chart may indicate either a breakout or a risk of correction. For AC Immune (ACIU), the dynamics of this metric reflect the market valuation of its unique developments in precision vaccines. High R&D potential in neurobiology directly impacts the asset's investment attractiveness.